Systematic Review and Meta-Analysis of Diagnostic Accuracy of Endoscopic Ultrasound (EUS)-Guided Fine-Needle Aspiration (FNA) Using 22-gauge and 25-gauge Needles for Pancreatic Masses

Guo Tian
Haiwei Bao
Ju Li
Tian’an Jiang

Background: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has been used for detecting pancreatic cancer. We aimed to compare the diagnostic yield of both 22-gauge and 25-gauge EUS-FNA for the detection of pancreatic cancer.

Material/Methods: We searched the electronic databases including PubMed, EMBASE, Web of Science, Scopus, and Cochrane Library up to June 13, 2017. Two reviewers independently screened studies and extracted data.

Results: We analyzed data from 1824 patients from 16 included studies. The estimated pooled data for the 22-gauge needles reported sensitivity was 0.89 (0.83–0.93), specificity was 1.00 (0.74–1.00), positive LR was 485.28 (2.55–92 000) and negative LR was 0.11 (0.07–0.17). Results for the 25-gauge needles showed the pooled sensitivity, specificity, positive and negative LR was 0.90 (0.86–0.93), 0.99 (0.89–1.00), 59.53 (7.99–443.66), and 0.10 (0.07–0.14), respectively. The 25-gauge needle had significantly higher pooled sensitivity than the 22-gauge needle (0.90 vs. 0.87, $\chi^2=5.26$, $P=0.02$) while there was no difference in the pooled specificity (0.96 vs. 0.98, $\chi^2=2.12$, $P=0.15$). The quality of most studies was assessed favorable using QUADAS-2 (quality assessment of diagnostic accuracy studies-2).

Conclusions: Our findings revealed that the 25-gauge EUS-FNA used for pancreatic lesions could have a higher diagnostic yield than using 22-gauge EUS-FNA. Nevertheless, well-designed prospective studies recruiting more patients are needed.

MeSH Keywords: Diagnosis • Endoscopic Ultrasound-Guided Fine Needle Aspiration • Pancreatic Neoplasms

Abbreviations: EUS – endoscopic ultrasound; FNA – fine-needle aspiration; QUADAS-2 – quality assessment of diagnostic accuracy studies-2; PRISMA – Preferred Reporting Items for Systematic Reviews and Meta-Analyses; TP – true positive; FP – false positive; FN – false negative; TN – true negative; LR – likelihood ratios; DOR – diagnostic odds ratio; AUC-ROC – receiver operating characteristic curve; CA19-9 – carbohydrate antigen 19-9; CEA – carcinoembryonic antigen

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/911405
Pancreatic cancer is the fourth fatal cause of cancer-related death in the world, and lacks definite diagnostic markers and causes poor prognosis, with a 5-year survival rate of only 1% to 4% [1]. Judging whether the pancreatic tumors are benign or malignant is crucial in choosing the optimal management. The ability to achieve the diagnosis of pancreatic cancer in asymptomatic patients can enable patients to have curative resection and better prognosis. Although many diagnostic imaging and biomarkers, like carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA), for this disease have been studied, most of these generated suboptimal results owing to their limited sensitivity, specificity, and positive predictive value [2,3].

In recent years, emerging minimally invasive tests for pancreatic cancer have been reported and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a promising diagnostic tool for pancreatic cancer. Numerous studies have suggested favorable accuracy of EUS-FNA for solid pancreatic lesions using the 22-gauge or the 25-gauge needle. The effectiveness and accuracy of EUS-FNA are susceptible to some factors such as site, size, needle type, and operational experience. Needle selection for EUS-guided sampling can be complicated. Larger-bore needles might not always offer high-quality specimens [4]. Although 22-gauge needles could result in more samples, it could also add the risk of procedure-related complications like pancreatitis, hemorrhage, abdominal pain, perforation, and hypotension [5]. A previous study showed that the presence of bloody contamination and cellular debris in the 22-gauge needle made the pathological examinations difficult [6]. In EUS, the 25-gauge needle had less sampling but could more smoothly enter into the torqued trans-duodenal position for sampling pancreatic head or uncinate process lesions.

To date, only a small number of studies have been published in recent years related to which needles provided the better diagnostic yield, and results have been inconsistent. We performed this meta-analysis to contrast the differences in diagnostic yield of EUS-guided 22-gauge FNA with a 25-gauge EUS-FNA in sampling the pancreatic lesions.

Material and Methods

Search strategy

We conducted this systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [7], and performed a systematic literature search from PubMed, EMBASE, Web of Science, Scopus, and Cochrane Library up to June 13, 2017 using the following words: 22-gauge, 25-gauge, EUS, endoscopic ultrasonography, FNA, pancreatic, cancer (Supplementary Text 1). We checked and found the potential published studies in additional literatures and previous meta-analyses [2,3]. All studies were searched with no language limitations. In cases where the necessary information was not available in articles, we also tried to email corresponding authors to obtain the required data.

Inclusion criteria

Studies fulfilling the following criteria were eligible for assessing diagnostic accuracy for pancreatic cancer: 1) reference standard for pancreatic cancer diagnosed by pathology on surgical specimen, or clinical follow-up (clinical and/or imaging studies) beyond 6 months indicating whether there was tumor progression or not; 2) access to the values of true positive (TP), false positive (FP), false negative (FN), and true negative (TN) of both 22-gauge and 25-gauge EUS-FNA.

Exclusion criteria

Studies were excluded if the following items were present: 1) review, guidelines and meeting abstracts; 2) study population overlapped with other studies; 3) non-human studies. Two reviewers independently checked and screened the studies from the literature. Disagreements existing were finally decided through a third reviewer.

Data extraction and quality assessment

Two individuals extracted data from the eligible articles using a predefined protocol, including author, type of study, country, race, number of patients, tumor size, site, age, gender, the reference standard category, length of follow-up, and complications. If potential diagnostic data were not available in a paper, an email was sent to the authors for these data. All studies in this meta-analysis underwent quality assessment using the quality assessment of diagnostic accuracy studies-2 (QUADAS-2). The tool comprised 4 key domains (patient selection, index test, reference standard, and flow of patients through the study) were each rated based on the risk of bias, and the first 3 domains were also appraised for concerns about applicability [8]. Any disagreements were resolved by discussion between authors.

Statistical analysis

For the existing or derived 2×2 contingency tables deriving from TP, FP, FN, and TN on the basis of consistency between biopsy result and surgical pathology or clinical radiologic result. In the eligible studies, we evaluated values of sensitivity and specificity and 95% confidence interval (CI). We evaluated
the pooled sensitivity, specificity, positive and negative likelihood ratios (LR), the diagnostic odds ratio (DOR), and the receiver operating characteristic curve (AUC-ROC) of EUS-guided FNA for pancreatic cancer using a bivariate mixed-effects regression model. We estimated statistical heterogeneity via the $I^2$ statistic [9]. Threshold effect was estimated through the Spearmen correlation coefficient. We used funnel plots and Egger’s test to detect a potential publication bias [10]. We ruled that $P<0.05$ was statistical significant as for 2-sided tests. All statistical analyses were processed with Stata 12.0.

Results

Characteristics of eligible studies in the final analysis

Of 4036 records screened for titles or abstracts, 4020 papers were excluded and finally we found 16 articles that fulfilled the inclusion criteria (Figure 1), which comprised 6 retrospective and 10 prospective studies [11–26]. The baseline characteristics of the included studies are displayed in Table 1. Seven of the 16 included studies were done in Asian countries, 6 in North American countries, and 3 in European countries. Of 1824 recruited patients, 1108 patients with pancreatic masses underwent biopsies using 22-gauge needles and 877 patients by 25-gauge needles. Regarding the results of the quality estimation according to QUADAS-2, most studies were considered as favorable quality, part of which had unclear blind methods and length of follow-up (Table 2).

Meta-analysis of accuracy of EUS-FNA for diagnosis of pancreatic cancers

Overall, the diagnostic accuracy of 22-gauge and 25-gauge needles was high. The pooled data for 22-gauge needles reported sensitivity of 0.89 (0.83–0.93), specificity of 1.00 (0.74–1.00), positive LR of 485.28 (2.55–92 000), and negative LR of 0.11 (0.07–0.17). And results for 25-gauge needles showed pooled sensitivity, specificity, positive LR, and negative LR of 0.90 (0.86–0.93), 0.99 (0.89–1.00), 59.53 (7.99–443.66), and 0.10 (0.07–0.14), respectively (Figure 2 and Supplementary Figure 1).

We compared the diagnostic accuracy of these 2 types of needles, and found that the pooled sensitivity was significantly higher in the 25-gauge needle (0.90 vs. 0.87, $\chi^2=5.26$, $P=0.02$), and slightly non-significant in pooled specificity (0.96 vs. 0.98, $\chi^2=2.12$, $P=0.15$). The AUC of SROC plots was both 0.97 (0.95–0.98) in 22-gauge and 25-gauge EUS-FNA (Figure 3). Threshold effects were not significant in the 2 groups (25-gauge: $r=0.033$, $P=0.905$; 22-gauge: $r=0.190$, $P=0.480$).

Sensitivity analysis and publication bias

Sensitivity analysis showed robust results and no difference after every study was ruled out. However, some significant evidence of publication bias was detectable across studies (25-gauge: $t=−3.02$, $P=0.009$; 22-gauge: $t=−5.14$, $P<0.001$).

Discussion

Pancreatic cancer is a devastating disease with a great burden on patients, for which a rapid and correct diagnosis is necessary. Earlier diagnosis might increase survival by estimated 30% to 40% [3]. We carefully reviewed the included studies to appraise the diagnostic accuracy of EUS-guided FNA for pancreatic cancer comparing the 22-gauge needle and the 25-gauge needle. Results from the meta-analysis showed that the 25-gauge needle had significantly higher pooled sensitivity than the 22-gauge needle (0.90 vs. 0.87, $\chi^2=5.26$, $P=0.02$) while there was not a significant difference in pooled specificity (0.96 vs. 0.98, $\chi^2=2.12$, $P=0.15$).

The diagnostic accuracy across studies had a similar heterogeneity (22-gauge: sensitivities 0.59 to 1.00; specificities 0.50 to 1.00; 25-gauge: sensitivities 0.68 to 1.00; specificities 0.80 to 1.00), both of which might showed that the methods are favorable. The heterogeneity in individual studies might result from the difference of study quality, prevalence, distribution of lesions, tumor size, or sample size. Although the pooled assessment of sensitivity and negative LR were fine, we should make a cautious conclusion. DOR combined the negative and curvilinear correlations between sensitivities and specificities, and we noted heterogeneity from studies regarding the different thresholds [27]. Thus, DOR might provide evidence for finding and treating patients earlier. In addition, SROC curves for EUS-FNA in pancreatic cancers showed that the AUC values were approximately close to 1 (AUC=0.97), which represented a favorable method to diagnose this disease. Higher positive LR revealed greater chance predicting adverse results while lower negative LR showed greater probability of achieving
| Author                  | Type of study | Country     | Number of patients (22G/25G) | Tumor size, mm (22G/25G) | Site (22G/25G) | Age (22G/25G) | Gender (M/F) (22G/25G) | Reference standard | Follow-up, months | Complication |
|------------------------|---------------|-------------|-----------------------------|--------------------------|---------------|---------------|------------------------|------------------|------------------|--------------|
| Imazu H et al. 2009    | Prospective   | Japan       | 12/12                       | NA                       | 8 head; 3 body; 1 tail | NA            | NA                     | Surgical pathology | NA               | No           |
| Lee JH et al. 2009     | Prospective   | America     | 12/12                       | NA                       | 7 head or uncinate process; 3 body; 2 peripancreatic region | NA            | NA                     | Surgical pathology or clinical follow-up | 12.44            | No           |
| Siddiqui UD et al. 2009| Prospective   | America     | 64/67                       | 30.2                     | 83 head          | 70.4          | 35/29; 47/20           | Surgical pathology or clinical follow-up | NA               | No           |
| Sakamoto H et al. 2009 | Prospective   | Japan       | 24/24                       | 32.8                     | 6 head; 6 uncinate process; 12 body or tail | NA            | NA                     | Surgical pathology or clinical follow-up | 12               | NA           |
| Yussuf TE et al. 2009  | Retrospective | America     | 540/302                     | NA                       | 410 head; 100 body; 23 tail/NA | 65/69         | 300/240; 172/130       | Surgical pathology or clinical follow-up | 6.5              | No           |
| Siddiqui AA et al. 2010| Retrospective | America     | 26/17                       | NA                       | 65.8±11.2       | NA            | NA                     | Surgical pathology or clinical follow-up | 6                | NA           |
| Camellini L et al. 2011| Retrospective | Italy       | 43/41                       | 27±12/28±11              | 31 head/uncinate process/33 head/uncinate process | 66/67         | NA                     | Surgical pathology or clinical follow-up | 6                | NA           |
| Fabbri C et al. 2011   | Prospective   | Italy       | 50/50                       | 29±0.7                   | 34 head; 8 uncinate process; 8 body | 68.2±7.4      | 30/20                   | Surgical pathology or clinical follow-up | 10.2             | (6–27) No |
| Uehara H et al. 2011   | Retrospective | Japan       | 54/66                       | NA                       | 56 head; 42 body; 22 tail | 63.31         | 72/43                   | Surgical pathology or clinical follow-up | NA               | 2 pancreatitis |
| Suzuki R et al. 2012   | Prospective   | Japan       | 20/20                       | 27.6±21.1/27.6±12.2      | 15 body or tail/11 body or tail | 67.9±8.5/67.5±8.7 | 11/9; 13/7           | Surgical pathology or clinical follow-up | 6                | No           |
| Lee JK et al. 2013     | Prospective   | Korea       | 94/94                       | 33±1.5/37±1.9            | 31 head or uncinate process; 63 head or tail/53 head or uncinate process; 41 body or tail | 58.5±11.8/61.3±11.1 | 54/40; 52/42         | Surgical pathology or clinical follow-up | 12               | 1 pancreatitis; 2 bleeding; 6 pancreatitis; 4 bleeding |
| Vilmann P et al. 2013  | Prospective   | Denmark     | 28/31                       | 30.9±14.46/28.4±12.1     | NA             | 62±13.6/64±11.4 | NA                     | Surgical pathology or clinical follow-up | 6                | No           |
| Berzosa M et al. 2015  | Retrospective | America     | 56/56                       | 33                       | 33 head; 5 uncinate process; 15 body; 2 tail; 6 peripancreatic lymph nodes | 62±14.4       | 35/26                   | Surgical pathology or clinical follow-up | 6                | NA           |
| Yang MJ et al. 2015    | Retrospective | Korea       | 38/38                       | 34.1±12.6/33.8±16.3      | 21 head or uncinate process; 17 body or tail/17 head or uncinate process; 21 body | 61.8±11.4/63.0±12.6 | 17/21; 18/20         | Surgical pathology or clinical follow-up | 8                | No           |
| Mavrogenis G et al. 2015| Prospective   | America     | 19/19                       | 39                       | NA             | 69            | NA                     | Surgical pathology or clinical follow-up | 7                | No           |
| Park SW et al. 2016    | Prospective   | Korea       | 28/28                       | 35.3±17.1                | 24 head; 4 uncinate process; 18 body; 10 tail | 65.8±9.5      | 35/21                   | Surgical pathology or clinical follow-up | 6                | No           |

NA – not available.
better outcomes [28]. The 2 needles both indicated strong diagnostic accuracy for ruling in pancreatic cancers (positive LRs beyond 10), but had less value for ruling out pancreatic cancers (positive LRs around 0.1).

In our results, some explanations should be considered for the higher accuracy of 25-gauge FNA needle in sampling pancreatic lesions. In these studies, most lesions were located in the head and uncinate process of the pancreas. Although the 22-gauge FNA needle could be useful for diagnosis with the pancreatic uncinate and head masses, its application in this scenario is limited. In this study, the selection bias might result in the underestimation of the true diagnostic performance for 22-gauge EUS-FNA. It has been reported that the 25-gauge needle had higher diagnostic accuracy for pancreatic tumors compared to that of the 22-gauge needle (91.7% vs. 75%) [11], and the 25-gauge EUS-FNA was also reported to be superior to 22-gauge EUS-FNA in technical success rate because of its flexibility with thinner caliber [29], especially for hard lesions needing extreme scope bending, and less complications.

To explain the results appropriately, several limitations should be noted in future research. First, the main source of bias within studies was associated with reporting of the reference standard and patient selection. Many studies used 2 approaches (surgical pathology or clinical follow-up) to confirm pancreatic cancer, which could affect the diagnostic accuracy. Second, blinding to the reference standard was not explicitly stated in some studies, which might lead to a risk of bias for results interpretation in these studies. Third, the length of follow-up in the included studies was not long, and it this might increase the risk of false-negative cases. Fourth, existing publication bias might also lead the physician to overestimate the availability of both these needles.

Despite the aforementioned limitations, we carefully conducted a systematic literature search using a predefined protocol, and tried to minimize the risk of publication bias by reading all potential studies from the citations in other literatures. The risk of bias was seriously evaluated using QUADAS-2. Data extracting was analyzed through a bivariate mixed-effects regression model.

### Table 2. Quality assessment of included studies using QUADAS-2.

| Author                      | Risk of bias | Applicability concerns |
|-----------------------------|--------------|------------------------|
|                            | Patient selection | Index test | Reference standard | Flow & timing | Patient selection | Index test | Reference standard |
| Imazu H et al., 2009        | LR           | LR                     | LR                  | UR           | HR                 | UR         | LR                 |
| Lee JH et al., 2009         | LR           | LR                     | LR                  | LR           | LR                 | LR         | LR                 |
| Siddiqui UD et al., 2009    | LR           | LR                     | UR                  | LR           | LR                 | LR         | LR                 |
| Sakamoto H et al., 2009     | LR           | LR                     | LR                  | LR           | LR                 | LR         | LR                 |
| Yusuf TE et al., 2009       | LR           | LR                     | LR                  | LR           | LR                 | LR         | LR                 |
| Siddiqui AA et al., 2010    | LR           | LR                     | UR                  | LR           | LR                 | LR         | LR                 |
| Camellini L et al., 2011    | LR           | LR                     | LR                  | LR           | HR                 | LR         | LR                 |
| Fabbri C et al., 2011       | LR           | LR                     | LR                  | LR           | LR                 | LR         | LR                 |
| Uehara H et al., 2011       | LR           | LR                     | UR                  | LR           | LR                 | LR         | LR                 |
| Suzuki R et al., 2012       | LR           | LR                     | UR                  | LR           | LR                 | LR         | LR                 |
| Lee JK et al., 2013         | LR           | LR                     | LR                  | UR           | LR                 | LR         | LR                 |
| Vilmann P et al., 2013      | LR           | LR                     | LR                  | LR           | LR                 | LR         | LR                 |
| Berzosa M et al., 2015      | LR           | LR                     | UR                  | LR           | LR                 | LR         | LR                 |
| Yang MJ et al., 2015        | LR           | LR                     | LR                  | LR           | LR                 | LR         | LR                 |
| Mavrogenis G et al., 2015   | LR           | LR                     | LR                  | LR           | LR                 | LR         | LR                 |
| Park SW et al., 2016        | LR           | LR                     | LR                  | LR           | LR                 | LR         | LR                 |

LR – low risk; HR – high risk; UR – unclear risk.
Figure 2. Forest plots showing sensitivity (A1, A2) and specificity (B1, B2) of all studies diagnosing pancreatic cancers by 22-gauge and 25-gauge endoscopic ultrasound-guided fine-needle aspiration.
Conclusions

The meta-analysis suggested that 22-gauge and 25-gauge EUS-FNA for diagnosing pancreatic lesions had favorable results with a low risk of complications, but 25-gauge EUS-FNA might have a higher sensitivity for pancreatic tumor detection with good sensitivity. However, future well-designed prospective studies are required to identify the feasibility of different EUS-FNA needles for pancreatic lesions and address knowledge gaps.

Conflict of interest

None.

Supplementary Materials

Supplementary Text 1. Search strategy.

Search strategy:

Pubmed
1. ‘endoscopic ultrasonography’ OR EUS OR ‘ultrasonic endoscope’
2. 22 AND 25 AND pancreas*
3. neoplasm OR cancer OR tumor OR tumour OR carcinoma OR oncology OR oncologic
   #1 AND #2 AND #3
5. ‘endoscopic ultrasonography’[Mesh]
6. ‘pancrea’ [Mesh]
7. ‘cancer’ [Mesh]
8. #5 OR #6 OR #7
9. #4 OR #8

Embase
1. ‘EUS’: ab,ti
2. ‘endoscopic ultrasonography’: ab,ti
3. ‘ultrasonic endoscope’: ab,ti
4. #1 OR #2 OR #3
5. ‘22’: ab,ti
6. ‘25’: ab,ti
7. ‘pancrea’: ab,ti
8. #5 OR #6 OR #7
9. ‘neoplasm’: ab,ti
10. ‘cancer’: ab,ti
11. ‘tumor’: ab,ti
12. ‘tumour’: ab,ti
13. ‘carcinoma’: ab,ti
14. ‘oncology’: ab,ti
15. ‘oncologic’: ab,ti
16. #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15
17. #4 AND #8 AND #16

Scopus
1. TITLE-ABS-KEY (‘EUS’)
2. TITLE-ABS-KEY (‘endoscopic ultrasonography’)
3. TITLE-ABS-KEY (‘ultrasonic endoscope’)
4. #1 OR #2 OR #3
5. TITLE-ABS-KEY (‘22’)
6. TITLE-ABS-KEY (‘25’)
7. TITLE-ABS-KEY (‘pancrea’)

Figure 3. Summary SROC plot of studies diagnosing pancreatic cancers by 22-gauge (A) and 25-gauge (B) endoscopic ultrasound-guided fine-needle aspiration.
Supplementary Figure 1. Fagan nomogram for pancreatic cancers using 22-gauge (A) and 25-gauge (B) endoscopic ultrasound-guided fine-needle aspiration.
References:

1. Grzesiak JJ, Ho JC, Moossa AR et al: The integrin-extracellular matrix axis in pancreatic cancer. Pancreas, 2007; 35: 293–301
2. Madhoun MF, Wani SB, Rastogi A et al: The diagnostic accuracy of 22-gauge and 25-gauge needles in endoscopic ultrasound-guided fine needle aspiration of solid pancreatic lesions: A meta-analysis. Endoscopy, 2013; 45: 86–92
3. Xu MM, Jia HY, Yan LL et al. Comparison of two different size needles in endoscopic ultrasound-guided fine-needle aspiration for diagnosing solid pancreatic lesions: A meta-analysis of prospective controlled trials. Medicine, 2017; 96: e6802
4. Tangpricha V, Chen BJ, Swan NC et al: Twenty-one-gauge needles provide more cellular samples than twenty-five-gauge needles in fine-needle aspiration biopsy of the thyroid but may not provide increased diagnostic accuracy. Thyroid, 2001; 11: 973–76
5. Ji YB, Hebertmagge S, Trevino J et al: Randomized trial comparing the 22-gauge aspiration and 22-gauge biopsy needles for EUS-guided sampling of solid pancreatic mass lesions. Gastrointest Endosc, 2012; 76: 321–27
6. Fabbi C, Poliferno AM, Luigiano C et al: Endoscopic ultrasound-guided fine needle aspiration with 22- and 25-gauge needles in solid pancreatic masses: A prospective comparative study with randomisation of needle sequence. Dig Liver Dis, 2011; 43: 647–52
7. Moher D, Liberati A, Tetzlaff J et al: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. Int J Surg, 2010; 18: 889–96
8. Wade R, Corbett M, Eastwood A: Quality assessment of comparative diagnostic accuracy studies: Our experience using a modified version of the QUADAS-2 tool. Res Synth Methods, 2013; 4: 280–86
9. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med, 2002; 21: 1539–58
10. Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method. Biometrics, 2000; 56: 455–63(0)
11. Imazu H, Uchiyama Y, Kakutani H et al: A prospective comparison of EUS-guided FNA using 25-gauge and 22-gauge needles. Gastroenterol Res Pract, 2009, 2009: 546390
12. Lee JH, Stewart J, Ross WA et al: Blinded prospective comparison of the performance of 22-gauge and 25-gauge needles in endoscopic ultrasound-guided fine needle aspiration of the pancreas and peri-pancreatic lesions. Dig Dis Sci, 2009; 54: 2274–81
13. Sakamoto H, Kitano M, Komaki T et al: A prospective comparative study of the EUS-guided 25-gauge FNA needle with the 19-gauge Trucut needle and 22-gauge FNA needle in patients with solid pancreatic masses. J Gastroenterol Hepatol, 2009; 69: 384–90
14. Siddiqui UD, Rossi F, Rosenthal LS: EUS-guided FNA of solid pancreatic masses: A prospective, randomized trial comparing 22-gauge and 25-gauge needles. Gastrointest Endosc, 2009; 70: 1093–97
15. Yusuf TE, Ho S, Pavey DA et al: Retrospective analysis of the utility of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic masses, using a 22-gauge or 25-gauge needle system: A multicenter experience. Endoscopy, 2009; 41: 445–48
16. Siddiqui AA, Lyles T, Avula H et al: Endoscopic ultrasound-guided fine needle aspiration of pancreatic masses in a veteran population: Comparison of results with 22- and 25-gauge needles. Pancreas, 2010; 39: 685–86
17. Camellini L, Carlinfante G, Azzolini F et al: A randomized clinical trial comparing 22G and 25G needles in endoscopic ultrasound-guided fine-needle aspiration of solid lesions. Endoscopy, 2011; 43: 709–15
18. Fabbi C, Poliferno AM, Luigiano C et al: Endoscopic ultrasound-guided fine needle aspiration with 22- and 25-gauge needles in solid pancreatic masses: A prospective comparative study with randomisation of needle sequence. Dig Liver Dis, 2011; 43: 647–52
19. Uehara H, Ikezawa K, Kawada N et al: Diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration for suspected pancreatic malignancy in relation to the size of lesions. J Gastroenterol Hepatol, 2011; 26: 1256–61
20. Suzuki R, Irisawa A, Bhatani MS et al: Prospective evaluation of the optimal number of 25-gauge needle passes for endoscopic ultrasound-guided fine-needle aspiration biopsy of solid pancreatic lesions in the absence of an onsite cytopathologist. Dig Endosc, 2012; 24: 452–56
21. Lee JK, Lee KT, Choi ER et al: A prospective, randomized trial comparing 25-gauge and 22-gauge needles for endoscopic ultrasound-guided fine needle aspiration of pancreatic masses. Scand J Gastroenterol, 2013; 48: 752–57
22. Vilimann P, Sáfoiu A, Hollerbach S et al: Multicenter randomized controlled trial comparing the performance of 22 gauge versus 25 gauge EUS-FNA needles in solid masses. Scand J Gastroenterol, 2013; 48: 877–83
23. Bertosa M, Villa N, Elserag HB et al: Comparison of endoscopic ultrasound guided 22-gauge core needle with standard 25-gauge fine-needle aspiration for diagnosing solid pancreatic lesions. Endoscopic Ultrasound, 2015; 4: 28–33
24. Mavrogenis G, Weynad B, Sibille A et al: 25-gauge histology needle versus 22-gauge cytology needle in endoscopic ultrasonography-guided sampling of pancreatic lesions and lymphadenopathy. Endosc Int Open, 2015; 3: E63
25. Min JY, Yim H, Hwang IC et al: Endoscopic ultrasound-guided sampling of solid pancreatic masses: 22-gauge aspiration versus 25-gauge biopsy needles. BMC Gastroenterol, 2015; 15: 122
26. Woo PS, Jee CM, Moon LS et al: Prospective study for comparison of endoscopic ultrasound-guided tissue acquisition using 25- and 22-gauge core biopsy needles in solid pancreatic masses. Plos One, 2016; 11: e0154401
27. Cleophas TJ, Zwierserman AH: Meta-analyses of diagnostic studies. Clin Chem Lab Med, 2009; 47: 1351–54
28. Archibald S, Bhandari M, Thoma A: Users’ guides to the surgical literature: How to use an article about a diagnostic test. Evidence-Based Surgery Working Group. Can J Surg, 2001; 44: 17–23
29. Sakamoto H, Kitano M, Kamaki T et al. Prospective comparative study of the EUS guided 25-gauge FNA needle with the 19-gauge Trucut needle and 22-gauge FNA needle in patients with solid pancreatic masses. J Gastroenterol Hepatol, 2009; 24: 384–90